Filter Results:
(2,358)
Show Results For
- All HBS Web
(5,037)
- People (16)
- News (1,907)
- Research (2,358)
- Events (2)
- Multimedia (222)
- Faculty Publications (1,873)
Show Results For
- All HBS Web
(5,037)
- People (16)
- News (1,907)
- Research (2,358)
- Events (2)
- Multimedia (222)
- Faculty Publications (1,873)
Sort by
- 2021
- Working Paper
Regulatory Approval and Expanded Market Size
By: Benjamin Berger, Amitabh Chandra and Craig Garthwaite
Regulatory review of new medicines is often viewed as a hindrance to innovation by increasing the hurdle to bring products to market. However, a more complete accounting of regulation must also account for its potential market expanding effects through quality... View Details
Keywords: New Medicines; Regulatory Approval; Health Care and Treatment; Research and Development; Governing Rules, Regulations, and Reforms; Markets; Expansion; Pharmaceutical Industry
Berger, Benjamin, Amitabh Chandra, and Craig Garthwaite. "Regulatory Approval and Expanded Market Size." NBER Working Paper Series, No. 28889, June 2021.
- 25 Oct 2016
- First Look
October 25, 2016
Healthcare Group Acıbadem Healthcare Group is Turkey's only premium nationwide hospital network. This case focuses on Acıbadem’s potential expansion strategy after it was acquired by International Healthcare Holdings Berhad (IHH) in 2011, the world's second-largest... View Details
Keywords: Sean Silverthorne
- November 2020
- Supplement
Improving Access at VA (Update)
By: Ryan W. Buell
In November 2020, Chief Veterans Experience Officer, Lynda Davis, and Deputy Chief Veterans Experience Officer, Barbara C. Morton reflect on a busy four years leading the Veterans Experience Office at the U.S. Department of Veterans Affairs. The case provides an update... View Details
Keywords: Government; Service Management; Leading Change; Transformation; Service Operations; Management; Health Care and Treatment; Government Administration; Performance Improvement; Public Administration Industry; United States
Buell, Ryan W. "Improving Access at VA (Update)." Harvard Business School Supplement 621-070, November 2020.
- January 2014 (Revised June 2014)
- Supplement
23andMe: Genetic Testing for Consumers (B)
By: John A. Quelch and Margaret L. Rodriguez
Following the FDA's letter in November 2013, which ordered 23andMe to cease sales of its DNA test kits, observers wondered how co-founder and CEO, Anne Wojcicki, would guide the company in the presence of uncertainty. View Details
Keywords: Risk and Uncertainty; Genetics; Crisis Management; Health Care and Treatment; Product Development; Business and Government Relations; Biotechnology Industry; Consumer Products Industry; United States
Quelch, John A., and Margaret L. Rodriguez. "23andMe: Genetic Testing for Consumers (B)." Harvard Business School Supplement 514-095, January 2014. (Revised June 2014.)
- 2017
- Working Paper
Discretionary Task Ordering: Queue Management in Radiological Services
By: Maria Ibanez, Jonathan R. Clark, Robert S. Huckman and Bradley R. Staats
Work scheduling research typically prescribes task sequences implemented by managers. Yet employees often have discretion to deviate from their prescribed sequence. Using data from 2.4 million radiological diagnoses, we find that doctors prioritize similar tasks... View Details
Keywords: Discretion; Scheduling; Queue; Healthcare; Learning; Experience; Decentralization; Delegation; Behavioral Operations; Operations; Service Operations; Service Delivery; Performance; Performance Effectiveness; Performance Efficiency; Performance Improvement; Performance Productivity; Decisions; Time Management; Cost vs Benefits; Health Industry
Ibanez, Maria, Jonathan R. Clark, Robert S. Huckman, and Bradley R. Staats. "Discretionary Task Ordering: Queue Management in Radiological Services." Harvard Business School Working Paper, No. 16-051, October 2015. (Revised March 2017.)
- September 2009 (Revised August 2012)
- Case
Novasys Medical
By: Richard G. Hamermesh and Lauren Barley
Novasys has developed a new medical device and procedure for the treatment of female stress urinary incontinence that is cheaper and can be performed in doctors' offices. In spite of FDA approval, the American Medical Association has been unwilling to approve the... View Details
Keywords: Entrepreneurship; Governing Rules, Regulations, and Reforms; Policy; Health Care and Treatment; Health Disorders; Product Development; Business and Government Relations; Medical Devices and Supplies Industry; United States
Hamermesh, Richard G., and Lauren Barley. "Novasys Medical." Harvard Business School Case 810-027, September 2009. (Revised August 2012.)
- January 2023
- Case
The END Fund: To Eliminate Neglected Tropical Diseases
By: V. Kasturi Rangan and Courtney Han
Founded in 2012, the END fund focused on eliminating five Neglected Tropical Diseases that accounted for 80% of the tropical diseases affecting nearly 1.5 billion people worldwide. Its roughly $25 million/year annual budget was fully committed when it got news that the... View Details
Keywords: Nonprofit Organizations; Health Disorders; Health Care and Treatment; Resource Allocation; Global Range; Decisions; Investment Funds
Rangan, V. Kasturi, and Courtney Han. "The END Fund: To Eliminate Neglected Tropical Diseases." Harvard Business School Case 523-063, January 2023.
- August 2008 (Revised September 2008)
- Case
The Flaxil Label (B)
This case focuses on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The outcome of the negotiation would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil. The negotiation is quite... View Details
Keywords: Governance; Risk and Uncertainty; Value Creation; Negotiation; Attitudes; Health Care and Treatment; Government Administration; Pharmaceutical Industry; United States
Barron, Greg M. "The Flaxil Label (B)." Harvard Business School Case 909-002, August 2008. (Revised September 2008.)
- Article
Use of Crowd Innovation to Develop an Artificial Intelligence-Based Solution for Radiation Therapy Targeting
By: Raymond H. Mak, Michael G. Endres, Jin Hyun Paik, Rinat A. Sergeev, Hugo Aerts, Christopher L. Williams, Karim R. Lakhani and Eva C. Guinan
Importance: Radiation therapy (RT) is a critical cancer treatment, but the existing radiation oncologist work force does not meet growing global demand. One key physician task in RT planning involves tumor segmentation for targeting, which requires substantial... View Details
Keywords: Crowdsourcing; AI Algorithms; Health Care and Treatment; Collaborative Innovation and Invention; AI and Machine Learning
Mak, Raymond H., Michael G. Endres, Jin Hyun Paik, Rinat A. Sergeev, Hugo Aerts, Christopher L. Williams, Karim R. Lakhani, and Eva C. Guinan. "Use of Crowd Innovation to Develop an Artificial Intelligence-Based Solution for Radiation Therapy Targeting." JAMA Oncology 5, no. 5 (May 2019): 654–661.
- August 2003 (Revised August 2006)
- Case
I've Got Rhythm: Selling Cardiac Rhythm Management Devices
By: Regina E. Herzlinger, William Lagor, Christopher Perry and Scott St. Germain
The head of sales and marketing in a large medical devices firm must decide how to assign his sales force. He compares selling in the pharma, specialty pharma, and device industries and analyzes the reasons for the differences. View Details
Keywords: Health Care and Treatment; Marketing Strategy; Industry Structures; Sales; Salesforce Management; Medical Devices and Supplies Industry
Herzlinger, Regina E., William Lagor, Christopher Perry, and Scott St. Germain. "I've Got Rhythm: Selling Cardiac Rhythm Management Devices." Harvard Business School Case 304-012, August 2003. (Revised August 2006.)
- October 1992 (Revised September 1993)
- Case
Nopane Advertising Strategy
By: David E. Bell
Nopane is a proprietary drug that sells in much of the United States. It faces substantial competition. The brand manager is undertaking an experiment to determine whether ad copy should be emotional-based or rational-based. The data and associated regression results... View Details
Keywords: Competition; Intellectual Property; Advertising; Health Care and Treatment; Brands and Branding; Product Marketing; Pharmaceutical Industry; United States
Bell, David E. "Nopane Advertising Strategy." Harvard Business School Case 893-005, October 1992. (Revised September 1993.)
- September 2009
- Article
A Detailed Analysis of the Reduction Mammaplasty Learning Curve: A Statistical Process Model for Approaching Surgical Performance Improvement
By: Matthew Carty MD, Rodney Chan, Robert S. Huckman, Daniel C. Snow and Dennis Orgill
Background: The increased focus on quality and efficiency improvement within academic surgery has met with variable success among plastic surgeons. Traditional surgical performance metrics, such as morbidity and mortality, are insufficient to improve the... View Details
Keywords: Experience and Expertise; Health Care and Treatment; Medical Specialties; Outcome or Result; Performance Efficiency; Performance Improvement
Carty, Matthew, MD, Rodney Chan, Robert S. Huckman, Daniel C. Snow, and Dennis Orgill. "A Detailed Analysis of the Reduction Mammaplasty Learning Curve: A Statistical Process Model for Approaching Surgical Performance Improvement." Plastic and Reconstructive Surgery 124, no. 3 (September 2009): 706–714.
- September 2024
- Case
Myeloma Investment Fund
By: Kyle Myers and Scott Sawaya
This case explores a critical decision facing the Myeloma Investment Fund (MIF) as it evaluates two investment opportunities aimed at accelerating a cure for multiple myeloma.
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
The MIF, a venture philanthropy fund, must choose between two distinct paths. One... View Details
Keywords: Venture Philanthropy; Biomedical Research; Investing For Impact; Innovation ＆ Entrepreneurship; Venture Capital; Science-Based Business; Philanthropy and Charitable Giving; Decision Making; Health Care and Treatment; Biotechnology Industry; Pharmaceutical Industry
Myers, Kyle, and Scott Sawaya. "Myeloma Investment Fund." Harvard Business School Case 625-047, September 2024.
- February 2002 (Revised August 2002)
- Case
Inhale Therapeutics: Executing and Growing the Business Model
Inhale is about to bring a novel technology to market that uses inhalation to administer drugs that formerly required injection. Inhale must now decide which way to evolve its business model. This will determine the future direction of growth for the company. View Details
Keywords: Business Model; Technological Innovation; Health Care and Treatment; Growth and Development Strategy; Medical Devices and Supplies Industry
Chesbrough, Henry W., and Gillian Morris. "Inhale Therapeutics: Executing and Growing the Business Model." Harvard Business School Case 602-132, February 2002. (Revised August 2002.)
- 17 Jan 2012
- First Look
First Look: January 17
reference points or anchors to simplify the complex tasks of valuation and negotiation. Read the paper: http://people.hbs.edu/mbaker/cv/papers/refpt.pdf The Four Habits of High-Value Health Care... View Details
Keywords: Sean Silverthorne
- 11 Sep 2007
- First Look
First Look: September 11, 2007
Herzlinger Publication:McGraw-Hill, 2007 Abstract In the battle for U.S. health care, patients and doctors are losing. Who Killed Health Care? shows how to win the war. One of the nation's most respected... View Details
Keywords: Martha Lagace
- 16 Feb 2016
- First Look
February 16, 2016
https://cb.hbsp.harvard.edu/cbmp/product/516027-PDF-ENG Harvard Business School Case 816-060 athenahealth's More Disruption Please Program No abstract available. Purchase this case: https://cb.hbsp.harvard.edu/cbmp/product/816060-PDF-ENG Harvard Business School Case... View Details
Keywords: Sean Silverthorne
- January 2009
- Teaching Note
Biocon: Launching a New Cancer Drug in India (TN)
By: Sunil Gupta and Das Narayandas
Teaching Note for [508026]. View Details
- August 2017 (Revised July 2018)
- Case
MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work
By: Elie Ofek and Amanda Dai
In June 2014, MannKind Corporation announced that after years of development and billions of dollars in expenses, the FDA had finally approved its drug, Afrezza. MannKind would thus be the only company with an inhalable insulin on the market. As an alternative to... View Details
Keywords: Health Care and Treatment; Product Launch; Product Positioning; Marketing Strategy; Adoption; Pharmaceutical Industry
Ofek, Elie, and Amanda Dai. "MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work." Harvard Business School Case 518-031, August 2017. (Revised July 2018.)
- January 2007 (Revised December 2007)
- Case
PSI: Social Marketing Clean Water
By: V. Kasturi Rangan, Nava Ashraf and Marie Bell
Senior management at PSI, arguably the world's largest and most successful social marketer with impressive achievements in the field of family planning, HIV/AIDS, and malaria prevention must determine what to do about their slow-to-take-off clean water initiative.... View Details
Keywords: Investment Funds; Health Care and Treatment; Social Marketing; Natural Environment; Social Enterprise; Business Strategy
Rangan, V. Kasturi, Nava Ashraf, and Marie Bell. "PSI: Social Marketing Clean Water." Harvard Business School Case 507-052, January 2007. (Revised December 2007.) (Request a courtesy copy.)